Zai Lab Signs an Exclusive License Agreement with Turning Point Therapeutics for Repotrectinib in Greater China

 Zai Lab Signs an Exclusive License Agreement with Turning Point Therapeutics for Repotrectinib in Greater China

Zai Lab Signs an Exclusive License Agreement with Turning Point Therapeutics for Repotrectinib in Greater China

Shots:

  • Turning Point to receive $25M as upfront, $151M as development, regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive rights to develop and commercialize repotrectinib in Greater China including China, Hong Kong, Macau, and Taiwan
  • Zai Lab anticipates opening additional sites for the TRIDENT-1 P-II registrational clinical study of repotrectinib, currently active in 11 countries globally and enrolling patients with ROS1-positive advanced NSCLC and NTRK-positive solid tumors
  • The collaboration strengthens Zai Lab solid tumor’s pipeline in China, particularly in lung cancer. Repotrectinib is an investigational TKI designed to effectively target ROS1 and TRK A/B/C with potential to treat TKI-naïve or -pretreated patients

Click here to read full press release/ article | Ref: PRNewswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post